financetom
Business
financetom
/
Business
/
Neogen's Preliminary Fiscal Q2 Adjusted Earnings Unchanged, Revenue Increases; Fiscal 2025 Sales Outlook Lowered
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Neogen's Preliminary Fiscal Q2 Adjusted Earnings Unchanged, Revenue Increases; Fiscal 2025 Sales Outlook Lowered
Jan 10, 2025 4:51 AM

07:25 AM EST, 01/10/2025 (MT Newswires) -- Neogen (NEOG) reported preliminary fiscal Q2 adjusted earnings Friday of $0.11 per share, unchanged from a year earlier.

Analysts polled by FactSet expected $0.10.

Revenue for the quarter ended Nov. 30 was $231.3 million, compared with $229.6 million a year earlier.

Analysts polled by FactSet expected $227.2 million.

The company said it now expects fiscal 2025 revenue of $905 million to $925 million, compared with its previous guidance range of $925 million to $955 million.

Analysts polled by FactSet expect $935.3 million.

Neogen shares were down more than 2% in recent Friday premarket activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Synovus Financial Insider Sold Shares Worth $5,518,620, According to a Recent SEC Filing
Synovus Financial Insider Sold Shares Worth $5,518,620, According to a Recent SEC Filing
Jun 4, 2024
05:30 PM EDT, 06/04/2024 (MT Newswires) -- Eli Samaha, 10% Owner, on May 31, 2024, sold 219,963 shares in Synovus Financial (SNV PRE) for $5,518,620. Following the Form 4 filing with the SEC, Samaha has control over a total of 1,473,296 shares of the company, with 1,473,296 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/18349/000187758924000003/xslF345X03/primary_doc.xml ...
Inhibrx Biosciences Insider Bought Shares Worth $4,927,580, According to a Recent SEC Filing
Inhibrx Biosciences Insider Bought Shares Worth $4,927,580, According to a Recent SEC Filing
Jun 4, 2024
05:31 PM EDT, 06/04/2024 (MT Newswires) -- Jon Faiz Kayyem, Director, on May 31, 2024, executed a purchase for 286,786 shares in Inhibrx Biosciences ( INBX ) for $4,927,580. Following the Form 4 filing with the SEC, Kayyem has control over a total of 1,092,861 shares of the company, with 1,092,861 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/2007919/000200791924000006/xslF345X03/wk-form4_1717536444.xml Price: 17.48, Change: +0.27,...
Impinj Insider Sold Shares Worth $2,457,979, According to a Recent SEC Filing
Impinj Insider Sold Shares Worth $2,457,979, According to a Recent SEC Filing
Jun 4, 2024
05:30 PM EDT, 06/04/2024 (MT Newswires) -- Chris Diorio, Director, CEO, on May 31, 2024, sold 15,000 shares in Impinj ( PI ) for $2,457,979. Following the Form 4 filing with the SEC, Diorio has control over a total of 838,724 shares of the company, with 286,230 shares held directly and 552,494 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1114995/000141588924015421/xslF345X03/form4-06042024_090637.xml Price: 161.02, Change:...
Jfrog Insider Sold Shares Worth $632,594, According to a Recent SEC Filing
Jfrog Insider Sold Shares Worth $632,594, According to a Recent SEC Filing
Jun 4, 2024
05:31 PM EDT, 06/04/2024 (MT Newswires) -- Tali Notman, Chief Revenue Officer, on June 03, 2024, sold 20,308 shares in Jfrog ( FROG ) for $632,594. Following the Form 4 filing with the SEC, Notman has control over a total of 593,782 shares of the company, with 593,782 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1800667/000141588924015420/xslF345X03/form4-06042024_090643.xml ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved